The apolipoprotein E ε4 allele is associated with blunting of ketamine-Induced psychosis in schizophrenia: A preliminary report

Neuropsychopharmacology

Volumn 19, Issue 5, 1998, Pages 445-448

  Malhotra, Anil K ^a,c   Breier, Alan ^a   Goldman, David ^b   Picken, Lisa ^a   Pickar, David ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

APOE; Genotype; Ketamine; N Methyl d aspartate; Psychosis

Indexed keywords

APOLIPOPROTEIN; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; AFFECT; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AFFECT; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETAMINE; MALE; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA;

EID: 0032194946     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00031-1     Document Type: Article

References (17)

1. 4 dopamine receptor gene and measures of novelty seeking. Nature Genet. 12:1996;81-84.
2. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiat. 154:1997;805-811.
3. 4 receptor (D4DR) exon III polymorphism associated with human personality trait of novelty-seeking. Nature Genet. 12:1996;78-80.
4. Harada S., Agarwal D.P., Goedde H.W. Aldehyde dehydrogenase polymorphism and alcohol metabolism in alcoholics. Alcohol. 2:1985;391-392.
5. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 31:1990;545-548.
6. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremmer J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Psychomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiat. 51:1994;199-214.
7. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
8. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Müller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 274:1996;1527-1531.
9. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150. a.
10. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis. A study with ketamine Biol Psychiat. 42:1997;664-668. b.
11. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition. The effects of ketamine in healthy volunteers Neuropsychopharmacology. 14:1996;301-307. a.
12. 4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking. Mol Psychiat. 1:1996;388-391. b.
13. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet. 14:1996;55-61.
14. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep. 10:1962;799-812.
15. Pickar D., Malhotra A.K., Rooney W., Breier A., Goldman D. Apolipoprotein E ε4 allele and clinical phenotype in schizophrenia. Lancet. 350:1997;930-931.
16. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R - Patient Version 1.0 (SCID-P). 1990;American Psychiatric Press, Washington, DC.
17. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA. 92:1995;4725-4727.